Glucose 30% Labesfal (Glucose)

Glucose 30% Labesfal is used in clinical practice for several therapeutic purposes related to carbohydrate provision and fluid management.

• Management of hypoglycemia in patients unable to receive oral glucose.
• Component of parenteral nutrition regimens to supply caloric energy.
• Fluid and electrolyte replacement when combined with appropriate electrolytes.
• Dilution of other intravenous medications requiring a glucose carrier.
• Support during perioperative periods to maintain blood glucose levels.

Intravenous administration of a 30% glucose solution may be associated with a range of observed effects.

Common

• Transient increase in blood glucose levels shortly after infusion.
• Mild irritation or pain at the catheter insertion site.
• Shifts in serum electrolytes, most commonly a temporary decrease in potassium.
• Nausea, mild abdominal discomfort, or a feeling of fullness.

Serious

• Marked hyperglycemia that may progress to osmotic diuresis and dehydration.
• Fluid overload that can precipitate pulmonary edema, especially in patients with cardiac compromise.
• Development of hyperosmolar hyperglycemic state in susceptible individuals.
• Allergic reactions ranging from skin rash to anaphylactic shock.

When prescribing or administering Glucose 30% Labesfal, clinicians should consider several precautionary measures to ensure patient safety.

• Assess baseline blood glucose and electrolyte status before initiation.
• Adjust infusion rate in patients with renal or cardiac insufficiency to avoid fluid overload.
• Use compatible infusion sets and avoid mixing with incompatible drugs.
• Monitor for signs of hyperglycemia, especially in diabetic patients.
• Store the solution according to manufacturer guidelines and protect from light.
• Discard any solution that appears discolored or contains particles.
• Verify patient identity and prescription details to prevent medication errors.

Glucose 30% Labesfal can interact with other intravenous agents, influencing efficacy or safety.

Avoid

• Co‑administration with high‑dose insulin infusions without appropriate glucose monitoring.
• Simultaneous infusion of potassium chloride solutions, which may precipitate in high‑glucose concentrations.
• Mixing with calcium‑containing solutions that can cause precipitation.
• Use with certain antibiotics (e.g., aminoglycosides) that may have reduced stability in hypertonic glucose.

Use with caution

• Concurrent administration of diuretics that may exacerbate electrolyte disturbances.
• Concurrent parenteral nutrition components requiring careful osmolarity balance.
• Patients receiving corticosteroids, as they may increase glucose levels.
• Blood transfusions, where hyperglycemia can affect red cell metabolism.